"Assessing Competitiveness in the Microbiome Business"

Ildong Bioscience, a health functional food subsidiary of the Ildong Pharmaceutical Group, announced on June 12 that it participated in the "2026 Probiota America" held in Vancouver, Canada, from June 9 to 11 (local time) to explore new business opportunities.


Ildong Bioscience participated in the '2026 Probiota America' held in Vancouver, Canada, from the 9th to the 11th (local time). Ildong Bioscience

Ildong Bioscience participated in the '2026 Probiota America' held in Vancouver, Canada, from the 9th to the 11th (local time). Ildong Bioscience

View original image

At its exhibition booth, Ildong Bioscience promoted its microbiome business, including probiotics and postbiotics, and presented its latest academic research results in poster form. Specifically, the company introduced three studies: animal and human trials on sleep quality improvement with Bacillus coagulans IDCC 1201 (SPORABLE); and a safety study of Lactikacaseibacillus paracasei IDCC 3402, a new strain derived from the vaginal microbiome of Korean women.



A company representative said, "Through this event, we were able to assess our research and development capabilities and business competitiveness in the microbiome sector. Building on these research outcomes, we plan to expand the development of functional ingredients and products, and accelerate our efforts to enter both domestic and international markets."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing